AstraZeneca

Global Chronic Obstructive Pulmonary Disease Drugs Markets 2021-2025 - Strong Pipeline and New Drug Approvals & Growing Demand for Fixed-Dose Combinations - ResearchAndMarkets.com

Retrieved on: 
Monday, August 30, 2021
Health, Pharmaceutical, Industry, CAGR, Smoking, Viatris, Merck, Research, Prevalence, Novartis, COPD, Chronic obstructive pulmonary disease, AstraZeneca, A.D. Bedell Wholesale Co., Inc. v. Philip Morris Inc., GlaxoSmithKline, Pharmaceutical industry

The "Global Chronic Obstructive Pulmonary Disease Drugs Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Chronic Obstructive Pulmonary Disease Drugs Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The chronic obstructive pulmonary disease drugs market is poised to grow by $5.63 bn during 2021-2025, progressing at a CAGR of 5.68%
    The market is driven by the rising prevalence of COPD, strong pipeline and new drug approvals, and the growing demand for fixed-dose combinations.
  • The report on the chronic obstructive pulmonary disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The chronic obstructive pulmonary disease drugs market analysis includes the product segment and geographic landscape.

Global Biologic Therapeutics Market Report 2021-2025 - Strong R&D Pipeline, Patent Expiry of Major Biologics, and Increasing Investment in Development of Biologics - ResearchAndMarkets.com

Retrieved on: 
Monday, August 30, 2021
Health, Biotechnology, Industry, Novartis, Bristol-Myers Squibb Co. v. Superior Court, CAGR, Conditional sentence, AbbVie, Pfizer, AstraZeneca, M. Levin & Co, Inc, GlaxoSmithKline, Incidence, Pharmaceutical industry

The biologic therapeutics market is poised to grow by $226.61 bn during 2021-2025, progressing at a CAGR of 11.00%

Key Points: 
  • The biologic therapeutics market is poised to grow by $226.61 bn during 2021-2025, progressing at a CAGR of 11.00%
    The market is driven by strong R&D pipeline, patent expiry of major biologics, and increasing investment in development of biologics.
  • The report provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
  • Also, the biologic therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth.

Through CEO of Hanmi Science, CancerRop Issues KRW 20 Billion New Shares for Cooperation with Oxford Vacmedix

Retrieved on: 
Monday, August 30, 2021
Cancer, Recombinant, Research, World Health Organization, RNA, World, Precision medicine, RNA transfection, University of Oxford, WHO, CEO, AstraZeneca, COVID-19, Technology, Pharmaceutical industry, Management, Vaccine

On the 30th, CancerRop announced that it had decided to issue a capital increase of about 20 billion won through a third-party allocation to Lim Chong-Yoon, CEO of Hanmi Science and Chairman of Korea Biotechnology Industry Organization.

Key Points: 
  • On the 30th, CancerRop announced that it had decided to issue a capital increase of about 20 billion won through a third-party allocation to Lim Chong-Yoon, CEO of Hanmi Science and Chairman of Korea Biotechnology Industry Organization.
  • Lim Chong-Yoon will invest 277,778 common shares of Hanmi Science in CancerRop, and in return, CancerRop will issue 5,614,823 common shares.
  • An official at CancerRop said, "This investment was made to cooperate with Oxford Vacmedix, established in 2021 as a spinout from Oxford University, which has world's first technology in cancer vaccine.
  • Currently, Oxford Vacmedix's CEO is from AstraZeneca, and CancerRop is the largest shareholder with a 43 percent stake.

Alucio™ Expands Executive Team with Proven Relationship Builder and Business Development Leader

Retrieved on: 
Monday, August 30, 2021
Industry, Epocrates, Strategic partnership, Library and information science, Efficiency, Bristol Myers Squibb, Biogen, WPP, MedImmune, CRO, Business development, Entrepreneurship, Senior, Lists of people executed in the United States, Marketing, Partnership, GlaxoSmithKline, Solution, SAN, Novartis, Medical science liaison, Vertex Pharmaceuticals, AstraZeneca, Management, Pharmaceutical industry

Beacon is a user-focused, cloud-based scientific exchange platform specifically designed for Medical Science Liaisons (MSLs) and other medical affairs professionals.

Key Points: 
  • Beacon is a user-focused, cloud-based scientific exchange platform specifically designed for Medical Science Liaisons (MSLs) and other medical affairs professionals.
  • "I'm very excited to become part of such a talented and successful team.
  • With nearly 20 years working in the healthcare and technology arenas, Marie brings a unique skill set and credible voice to Alucio.
  • Alucio is dedicated to the development of innovative software applications specifically for the life sciences industry.

Biotech Veteran David Kideckel Joins the Board of PharmaDrug

Retrieved on: 
Monday, August 30, 2021
Industry, Certification, University, Legislation, EMA, CSE, Knight Therapeutics, Leadership, The Company, Jazz Pharmaceuticals, Board of directors, Person, Research, Pharmacy, THIS, Doctor of Philosophy, Risk, GW Pharmaceuticals, Therapy, Alexion Pharmaceuticals, Board, OTC Markets Group, Adult, News, Cannabis, CEO, AstraZeneca, Health Canada, THE, Sale, FDA, Capital market, Bay Street, Pharmaceutical industry

David joins PharmaDrug after nearly 20 years of combined industry and capital markets experience, most recently serving as Managing Director, Senior Institutional Equity Research Analyst at ATB Capital Markets.

Key Points: 
  • David joins PharmaDrug after nearly 20 years of combined industry and capital markets experience, most recently serving as Managing Director, Senior Institutional Equity Research Analyst at ATB Capital Markets.
  • Daniel Cohen, Chairman and CEO of PharmaDrug, commented, "We are absolutely thrilled to add the expertise of a member of David's calibre to our Board of Directors.
  • David's unique combination of experience in big pharma, biotech and investment banking ideally suits PharmaDrug as it increasingly shifts its focus to a biotech strategy.
  • Pursuant to the terms and conditions of the Company's stock option plan, the PharmaDrug Board of Directors has approved the grant of 750,000 stock options to David Kideckel.

2021 Pipeline Insight Report on Myocardial Infarction - Featuring AstraZeneca, Mesoblast and Boehringer Ingelheim Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, August 30, 2021
Health, Clinical Trials, Cardiology, Myocardial infarction, ROA, Therapy, Aquaporin 1, Route, Administration, SGLT1, Discovery, Tissue, II, SGLT2, Clinical trial, Glucose, News, III, Cytokine, Bone marrow, AstraZeneca, Route of administration, Pharmaceutical industry

The "Myocardial Infarction - Pipeline Insight, 2021" clinical trials have been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Myocardial Infarction - Pipeline Insight, 2021" clinical trials have been added to ResearchAndMarkets.com's offering.
  • This "Myocardial infarction - Pipeline Insight, 2021," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Myocardial infarction pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Myocardial infarction R&D.
  • Myocardial infarction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Box Comments on Glass Lewis Recommendation

Retrieved on: 
Saturday, August 28, 2021
Networks, Internet, Data Management, Technology, Software, Momentum, Cloud, COVID, American Box Board Company Headquarters and Factory, SEC, Leadership, Chair, ALL, Review, Achievement, Board, Risk, Institutional Shareholder Services, CARD, Information technology, JLL, TSR, Board of directors, U.S. Securities and Exchange Commission, Glass, National Operating Committee on Standards for Athletic Equipment, Sidley Austin, Annual general meeting, Committee, ARE, Software as a service, COVID 19, P.C, CEO, History, Sale, Morgan Stanley, Record, McAfee, Proxy statement, Wilson Sonsini Goodrich & Rosati, Port and starboard, KKR, Organization, BLUE, Growth, ISS, BOX, CA, Professional Football Compensation Committee, NYSE, Proxy, AstraZeneca, Animal, Audit, Pharmaceutical industry, Film, Renewable energy, Management, Retail, Security (finance), Holding company

Box, Inc. (NYSE: BOX) today commented on a report published by Glass, Lewis & Co. (Glass Lewis) in connection with the election of the companys director nominees Dana Evan, Peter Leav and Aaron Levie at its 2021 Annual Meeting of Stockholders (Annual Meeting), to be held on September 9, 2021:

Key Points: 
  • Box, Inc. (NYSE: BOX) today commented on a report published by Glass, Lewis & Co. (Glass Lewis) in connection with the election of the companys director nominees Dana Evan, Peter Leav and Aaron Levie at its 2021 Annual Meeting of Stockholders (Annual Meeting), to be held on September 9, 2021:
    We strongly believe that Glass Lewis reached the wrong conclusion in its recent report.
  • Notably, Glass Lewis fails to acknowledge that significant changes have already been made and that the change agents are already on the Board.
  • Box is delivering improved operating and financial performance, including operating margin improvement and reacceleration of revenue growth, with sustained momentum across the business.
  • In its report, Glass Lewis ignores that Peter Feld has fixated on firing Boxs CEO in the absence of a sale, demonstrating his unwillingness to be open minded.

BreezoMeter’s New Wildfire Tracker Offers the Most Complete View of Fire Movement Available

Retrieved on: 
Thursday, August 26, 2021
Mobile, Wireless, Technology, Environment, Tornado, Weather, IOT, Electricity, Rain, Quality of life, GPS, Telecommunication, Technology, Movement, Air pollution, Snow, App Store (iOS/iPadOS), Travel, Flood, Health, Sunlight, Fire, Fear, Machine learning, Heart, AI, Wildfire, Multimedia, Pacific typhoon season, Overalls, National Interagency Fire Center, Risk, CEO, Google Play, Apple, Smoke, Visibility, Atmosphere, Pollen, API, AstraZeneca, Satellite navigation device, Mobile phone, Personal protective equipment, Coal

Effective immediately, consumers can get complete visibility into the perimeter of active fires and the quality of the air theyre breathing at Breezometer.com .

Key Points: 
  • Effective immediately, consumers can get complete visibility into the perimeter of active fires and the quality of the air theyre breathing at Breezometer.com .
  • BreezoMeters Wildfire Tracker, paired with its micro-local air quality, issues hourly-updated air quality reports to track moving wildfire smoke, including dedicated PM2.5 visualizations so users know what theyre breathing at any given moment.
  • BreezoMeters Wildfire Tracker complements its air pollution and pollen data, which is currently in use by companies in the healthcare, smart home, air purification, automotive, lifestyle and cosmetics industries.
  • Upcoming applications of BreezoMeters wildfire and air quality data include:
    GPS and live maps will factor wildfires and air quality into clean and safe route recommendations.

Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label

Retrieved on: 
Thursday, August 26, 2021
Health, FDA, General Health, Clinical Trials, Research, Science, Pharmaceutical, Population, Astellas Pharma, Drug development, Death, Pain, CIC, Incidence, Trial of the century, AbbVie, Constipation, Safety, Bloating, Food, Ironwood Pharmaceuticals, Time, Abdominal pain, Irritable bowel syndrome, IQVIA, Nationwide, Medication, NASDAQ, Mortality, Risk, Adult, Patient, Diarrhea, FDA, IBS-C, GC, Dehydration, AstraZeneca, FC, GC-C, Regulation of tobacco by the U.S. Food and Drug Administration, Medicine, Dietary supplement, Pharmaceutical industry, Phosphorus, Birth control, LINZESS (linaclotide), Ironwood Pharmaceuticals, LINZESS (LINACLOTIDE), IRONWOOD PHARMACEUTICALS

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for LINZESS (linaclotide) based on clinical safety data that has been generated thus far in pediatric studies.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for LINZESS (linaclotide) based on clinical safety data that has been generated thus far in pediatric studies.
  • This label update reflects a significant milestone, and we look forward to continuing to investigate the safety and efficacy of LINZESS for children.
  • LINZESS is not a laxative; it is the first medicine approved by the FDA in a class called GC-C agonists.
  • In the United States, Ironwood and AbbVie co-develop and co-commercialize LINZESS for the treatment of adults with IBS-C or CIC.

Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders

Retrieved on: 
Thursday, August 26, 2021
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Gastroesophageal reflux disease, Drug development, Investment, Global marketing, Venture, Series, Boehringer Ingelheim, Diabetes, Merck, PPI, RTW, Doctor of Philosophy, State, Therapy, Biogen, AstraZeneca, EE, CFO, Multimedia, Bluebird bio, Patient, Partnership, Gastroparesis, Daewoong Pharmaceutical, Enzyme inhibitor, Stomach, Roche, GI, Ironwood Pharmaceuticals, GERD, D2, MD, Pharmaceutical industry

Neurogastrx, Inc., a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced today the successful completion of a $60 million Series B crossover round led by Vivo Capital.

Key Points: 
  • Neurogastrx, Inc., a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced today the successful completion of a $60 million Series B crossover round led by Vivo Capital.
  • This pipeline includes fexuprazan for the treatment of erosive esophagitis (EE) and NG101 for the treatment of gastroparesis.
  • EE impacts 20 percent of the 65 million people in the U.S. who have gastroesophageal reflux disease (GERD), and gastroparesis impacts as many as 10 million Americans.
  • In conjunction with the Series B crossover and in preparation for a pivotal growth phase for the company, Neurogastrx is expanding its management team with three new hires.